Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin F Hartley
Dave Lunn
Adrian P Mander

Pharmaceutical statistics

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|July 29, 2024
Efficient Study Design and Analysis of Longitudinal Dose-Response Data Using Fractional PolynomialsBenjamin F Hartley, Dave Lunn, Adrian P Mander
Pharmaceutical Statistics|March 14, 2012
Escalation strategies for combination therapy Phase I trialsMichael J Sweeting, Adrian P Mander
Pharmaceutical Statistics|November 27, 2015
Do single-arm trials have a role in drug development plans incorporating randomised trials?Michael J Grayling, Adrian P Mander
Pharmaceutical Statistics|August 30, 2020
A stochastically curtailed two-arm randomised phase II trial design for binary outcomesMartin Law, Michael J Grayling, Adrian P Mander
Pharmaceutical Statistics|April 19, 2026
A Dose-Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D-OptimalityMaxine Ajimi, Benjamin Webb, Graham M Wheeler, et al.
Pharmaceutical Statistics|January 11, 2012
Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesisAdrian P Mander, James M S Wason, Michael J Sweeting, et al.
Pharmaceutical Statistics|June 17, 2014
Missing data sensitivity analysis for recurrent event data using controlled imputationOliver N Keene, James H Roger, Benjamin F Hartley, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|July 29, 2024
Efficient Study Design and Analysis of Longitudinal Dose-Response Data Using Fractional PolynomialsBenjamin F Hartley, Dave Lunn, Adrian P Mander
Pharmaceutical Statistics|March 14, 2012
Escalation strategies for combination therapy Phase I trialsMichael J Sweeting, Adrian P Mander
Pharmaceutical Statistics|November 27, 2015
Do single-arm trials have a role in drug development plans incorporating randomised trials?Michael J Grayling, Adrian P Mander
Pharmaceutical Statistics|August 30, 2020
A stochastically curtailed two-arm randomised phase II trial design for binary outcomesMartin Law, Michael J Grayling, Adrian P Mander
Pharmaceutical Statistics|April 19, 2026
A Dose-Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D-OptimalityMaxine Ajimi, Benjamin Webb, Graham M Wheeler, et al.
Pharmaceutical Statistics|January 11, 2012
Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesisAdrian P Mander, James M S Wason, Michael J Sweeting, et al.
Pharmaceutical Statistics|June 17, 2014
Missing data sensitivity analysis for recurrent event data using controlled imputationOliver N Keene, James H Roger, Benjamin F Hartley, et al.
Pageof 1